Sep
24
Novo Nordisk Developing Long-Acting HGH
September 24, 2008 |
BAGSVAERD, DENMARK, Sep 26, 2008 (MARKET WIRE via COMTEX) — Novo Nordisk provides update on corporate strategy at its Capital Markets Day.
Within the area of human growth hormone, Novo Nordisk will present its plans for label expansions as well as the clinical progress for a long-acting human growth hormone (HGH) compound which is currently in phase 2 clinical development. The phase 3 study for the use of Norditropin(R) for the treatment of dialysis patients is now expected to be completed in 2012 due to slower than anticipated recruitment of patients.
Comments
Recommended Links
GET YOUR FREE HGH &
ANTI-AGING REPORT!
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!